CANBRIDGE-B (01228) saw an intraday surge of nearly 18%, and as of the latest update, the stock rose 11.76% to HKD 2.09, with a turnover of HKD 10.22 million. The rally follows the recent announcement of the 2026 Beijing Inclusive Health Insurance coverage details, which included all three of CANBRIDGE's rare disease products. Notably, Gornin made its debut in the insurance program.

Gornin received market approval on May 13 this year. On July 2, the first prescription was issued at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, marking its official entry into clinical use. This development is expected to significantly improve drug accessibility for domestic patients.